Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Citalopram
Drug ID BADD_D00475
Description Citalopram belongs to a class of antidepressant agents known as selective _serotonin-reuptake inhibitors_ (SSRIs) and is widely used to treat the symptoms of depression. Its chemical structure is unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other prescribed antidepressants [FDA label]. Citalopram is also known as _Celexa_, and available in tablet and solution forms [FDA label]. This drug was initially approved by the FDA in 1998 [L5230].
Indications and Usage For the treatment of depression. Off-label indications include: treatment of mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA label].
Marketing Status Prescription
ATC Code N06AB04
DrugBank ID DB00215
KEGG ID D07704
MeSH ID D015283
PubChem ID 2771
TTD Drug ID D0Y5DO
NDC Product Code 69097-823; 42806-020; 70518-0561; 43063-385; 43353-112; 70518-2228; 65162-054; 67046-102; 71610-092; 0456-4020; 50090-5170; 69097-824; 68788-7899; 70518-2617; 43063-063; 70934-539; 65162-052; 54458-980; 69097-822; 70518-2553; 0054-0062; 52427-691; 60429-174; 67046-106; 76282-629; 61919-390; 76282-628; 50090-5172; 54458-889; 70518-2601; 70518-2671; 54458-981; 0378-6233; 71335-0541; 60429-173; 71610-412; 63850-3616; 65162-053; 0378-6231; 0456-4010; 42806-021; 76282-206; 68071-3034; 67046-101; 70518-0449; 60429-175; 70934-397; 43353-208; 50090-5175; 63629-6761; 0456-4040; 61919-389; 76282-208; 71610-422; 80425-0093; 76282-207; 0378-6232; 43353-091; 42806-019
Synonyms Citalopram | Cytalopram | Citalopram Hydrobromide | Lu-10-171 | Lu10171 | Seropram | Celexa
Chemical Information
Molecular Formula C20H21FN2O
CAS Registry Number 59729-33-8
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eczema23.03.04.006--
Ejaculation delayed21.03.01.0010.000083%Not Available
Ejaculation disorder21.03.01.0020.000125%
Ejaculation failure21.03.01.003--Not Available
Electric shock12.01.08.032--Not Available
Electrocardiogram abnormal13.14.05.0010.000167%Not Available
Electrocardiogram QRS complex prolonged13.14.05.0030.000875%Not Available
Electrocardiogram QT prolonged13.14.05.0040.005999%
Electrocardiogram ST segment elevation13.14.05.0250.000125%Not Available
Electrocardiogram T wave inversion13.14.05.0070.000292%Not Available
Emotional disorder19.04.02.0050.000250%Not Available
Emotional poverty19.04.02.0150.000250%Not Available
Encephalocele17.19.01.005; 03.10.02.0010.000022%Not Available
Encephalopathy17.13.02.001--
Endocrine disorder05.09.01.001--Not Available
Eosinophilia01.02.04.001--
Epilepsy17.12.03.0020.000542%Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Erection increased19.08.04.002; 21.03.01.0040.000208%Not Available
Eructation07.01.02.003--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.0150.000167%
Euphoric mood19.04.02.0060.000208%
Extensor plantar response17.02.01.0050.000083%Not Available
Extrapyramidal disorder17.01.02.007--
Extrasystoles02.03.02.0030.000417%Not Available
Eye disorder06.08.03.001--Not Available
Eye haemorrhage24.07.05.002; 06.07.02.0010.000125%Not Available
Eye pain06.08.03.002--
Eye swelling06.08.03.003--Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 37 Pages